Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
07
03
2023
accepted:
02
06
2023
medline:
26
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
epublish
Résumé
Secondary central nervous system lymphoma (SCNSL) is a rare and difficult to treat type of Non-Hodgkin lymphoma characterized by systemic and central nervous system (CNS) disease manifestations. In this study, 124 patients with SCNSL intensively treated and with clinical long-term follow-up were included. Initial histopathology, as divided in low-grade, other aggressive, and diffuse large B-cell lymphoma (DLBCL), was of prognostic significance. Overall response to induction treatment was a prognostic factor with early responding DLBCL-SCNSL in comparison to those non-responding experiencing a significantly better progression-free survival (PFS) and overall survival (OS). However, the type of induction regime was not prognostic for survival. Following consolidating high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT), DLBCL-SCNSL patients had better median PFS and OS. The important role of HDT-ASCT was further highlighted by favorable responses and survival of patients not responding to induction therapy and by excellent results in patients with
Identifiants
pubmed: 37492436
doi: 10.1097/HS9.0000000000000926
pmc: PMC10365212
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e926Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Déclaration de conflit d'intérêts
HT was supported within the EKFS clinician scientist program (University Medicine Göttingen). VN was supported within the FORUM female clinician scientist program (Ruhr-University Bochum). All the other authors have have no conflicts of interest to disclose.
Références
Br J Haematol. 2023 Jan;200(2):160-169
pubmed: 36408800
J Clin Oncol. 2003 Mar 15;21(6):1044-9
pubmed: 12637469
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2016 Feb 18;127(7):869-81
pubmed: 26702065
Lancet Haematol. 2016 May;3(5):e217-27
pubmed: 27132696
Haematologica. 2013 Mar;98(3):364-70
pubmed: 23242601
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
J Clin Oncol. 1989 Nov;7(11):1630-6
pubmed: 2809679
Lancet. 2009 Oct 31;374(9700):1512-20
pubmed: 19767089
Lancet Haematol. 2017 Nov;4(11):e510-e523
pubmed: 29054815
Haematologica. 2015 Sep;100(9):1199-206
pubmed: 26185174
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
J Clin Oncol. 2015 Nov 20;33(33):3903-10
pubmed: 26282634
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):884-888
pubmed: 28870642
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Cancer. 2000 Sep 15;89(6):1359-70
pubmed: 11002232
Leukemia. 2017 Apr;31(4):846-852
pubmed: 27843136
Hematol Oncol. 2017 Dec;35(4):497-503
pubmed: 27530779
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Am J Hematol. 2019 Sep;94(9):992-1001
pubmed: 31211434
Haematologica. 2023 Mar 01;108(3):882-888
pubmed: 36300776
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cancers (Basel). 2022 Apr 23;14(9):
pubmed: 35565230
Ann Oncol. 2004 Jan;15(1):129-33
pubmed: 14679132
Ann Oncol. 2007 Jan;18(1):149-157
pubmed: 17018708
Stat Med. 1984 Jan-Mar;3(1):35-44
pubmed: 6729287
Blood Adv. 2018 Jul 10;2(13):1595-1607
pubmed: 29986852
Lancet Haematol. 2021 Feb;8(2):e110-e121
pubmed: 33513372
Blood. 2009 Apr 23;113(17):3896-902
pubmed: 19144985
Haematologica. 2023 Mar 01;108(3):673-689
pubmed: 36384246
Ann Oncol. 2012 May;23(5):1267-1273
pubmed: 21989328